Drugs / TQB3728
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04523285 | Oct 2020 → Dec 2021 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05859373 | Jun 2023 → Sep 2024 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3728 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04523285 ↗ |
| Action | Inhibit | “TQB3728 is an inhibitor of apoptosis protein.” NCT05859373 ↗ |
| Modality | Small molecule | “TQB3728 tablets is a small molecule oral drug.” NCT04523285 ↗ |
| Route | Oral | “TQB3728 tablets administered orally, once a week in 28-day cycle.” NCT04523285 ↗ |